Elanco is joining the S&P MidCap 400 index, Boehringer Ingelheim launched a new swine vaccine, and Sarepta Therapeutics is being replaced in the index.
2 reports, 1 independent
Updated Sep 4
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Elanco is joining the S&P MidCap 400 index, Boehringer Ingelheim launched a new swine vaccine, and Sarepta Therapeutics is being replaced in the index.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Elanco
American healthcare company
Nothing else this week.
-
Boehringer Ingelheim
German pharmaceutical company
-
Sarepta Therapeutics
biopharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- StockStoryWhy Elanco (ELAN) Stock Is Trading Lower Today Shares of animal health company Elanco (NYSE:ELAN) fell 4.1% in the afternoon session after competitor Boehringer Ingelheim announced the U.S. launch of
- StockStoryWhy Elanco (ELAN) Stock Is Trading Up Today Shares of animal health company Elanco (NYSE:ELAN) jumped 4.4% in the morning session after the company announced it will be joining the S&P MidCap 400 ind